Treatment protocols for advanced ovarian tumors (stages III-IV), applied at the author's institute, are presented. Giving a short survey the outcome with single agent cyclophosphamide therapy (C; n = 82), combinations without cisplatin (CMV, CAV; n = 83) or combination with cisplatin (CAP; n = 41) has been compared. A significant difference between C and CMV/CAV groups could be found only in regards with remission period (p = 0.0004 and 0.0001). By the use of CAP the result became better not only in the extent and the duration of remission but in the survival as well as compared to that of the other groups. The importance of the extent of residual tumor is emphasized. Because of serious side effects of particularly cisplatin based, three drug combinations the use of combinations consisting of two drugs only can be recommended in accordance with literary data. By the estimation of the usefulness of second look operation's findings the radiotherapy with its consolidationary effect and also the significance of a maintaining or a second line cytostatic treatment are pointed out.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
KAT2B inhibits proliferation and invasion via inactivating TGF-β/Smad3 pathway-medicated autophagy and EMT in epithelial ovarian cancer.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, People's Republic of China.
Lysine acetyltransferase 2B (KAT2B) plays a crucial role in epigenetic regulation and tumor pathogenesis. Our study investigates KAT2B's function in epithelial ovarian cancer (EOC) using in vivo and in vitro methods. Immunohistochemistry showed the KAT2B expression in EOC tissues.
View Article and Find Full Text PDFDietary Advanced Glycation End Products and Superovulation with Gonadotropins Alters RAGE expression in the Ovaries Differently at Each Follicular Stage of Development.
Mol Cell Endocrinol
January 2025
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; Reproductive Medicine Associates of New York, Department of Obstetrics, Gynecology and Reproductive Science, Division of Reproductive Endocrinology and Infertility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The purpose of this study was to examine the deposition of advanced glycation end products (AGEs) and their receptors, RAGE, in ovarian follicles during folliculogenesis in mice fed high (H-AGE) or low (L-AGE) AGE diets and following superovulation with gonadotropins. We hypothesize that H-AGE diet is associated with increased AGE deposition and RAGE expression in various stages of ovarian follicular development, and superovulation with gonadotropins may alter these changes. C57BL/6J mice were fed low L-AGE (n=10) or H-AGE (n=10) diet for 12 weeks.
View Article and Find Full Text PDFMesonephric and Mesonephric-like Adenocarcinomas of the Gynecologic Tract: A Case Series and a Review of the Literature.
Int J Gynecol Pathol
January 2025
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology.
We sought to present and describe all cases of mesonephric adenocarcinoma (MNAC) and mesonephric-like adenocarcinomas (MLAs) at our institution. These cancers are rare, morphologically similar tumors of the female reproductive tract. In this case series, we present 13 new cases of MNAC/MLA that were identified at St.
View Article and Find Full Text PDFMesonephric-like adenocarcinoma of the ovary: a case study.
J Surg Case Rep
January 2025
Department of Pathology of the National Institute of Oncology, Ibn Sina University Hospital Center, Allal Al Fassi Avenue, Rabat 10100, Morocco.
Mesonephric-like adenocarcinoma (MLA) is a rare and newly recognized subtype of ovarian and endometrial carcinomas, introduced in the 2020 World Health Organization Classification. This tumor likely originates from Müllerian-derived tissues and often mimics more common ovarian cancers, leading to frequent misdiagnosis. This case study details a 36-year-old woman who presented with urinary symptoms following a hysterectomy.
View Article and Find Full Text PDFZNF165: A Pan-Cancer Biomarker with Prognostic and Therapeutic Potential.
Protein Pept Lett
January 2025
Scientific Research Center, Beijing ChosenMed Clinical Laboratory Co., Ltd. 101, 1F, Building 3, No.156 Jinghai 4th Road, Beijing Economic and Technological Development Zone, Beijing, 100176, China.
Background: The role of ZNF165 in only a few tumors has been reported. ZNF165 plays an important role in liver cancer, gastric cancer, and breast cancer, especially in regulating the immune microenvironment, promoting tumor cell proliferation and migration, and serving as a potential target for immunotherapy.
Objective: This study aimed to enhance an understanding of how the ZNF165 gene functions and influences cancer development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!